01 Industry overview
The bioscience industry at a glance
The U.S. bioscience industry generated $3.19 trillion in total economic output in 2025, while the global biotechnology market reached an estimated $1.38 trillion and remains concentrated in North America.
- $3.19T[63]
- U.S. output, 2025
- 2.31M[63]
- U.S. direct jobs, 2025
- $1.38T[83]
- Global market size, 2025
- 43.34%[83]
- North America share, 2025
- Market size
- The global biotechnology market was valued at $1,376.1 billion in 2025. In the United States, bioscience generated $3.19 trillion in total economic output in 2025, including $1.44 trillion in direct output.[83][63]
- Forecast & CAGR
- The global biotechnology market is projected to increase from $1,491.5 billion in 2026 to $4,334.8 billion by 2034, representing a 14.3% compound annual growth rate from 2026 to 2034.[83]
- Market share & regions
- North America accounted for 43.34% of the global biotechnology market in 2025. In U.S. bioscience, employment increased in 41 states, the District of Columbia, and Puerto Rico between 2021 and 2025, indicating a geographically broad domestic footprint.[83][63]
- Segmentation
- The U.S. industry is organized into five major subsectors: research, testing and medical laboratories; pharmaceuticals; medical devices and equipment; bioscience-related distribution; and agricultural feedstock and industrial biosciences. In 2025, bioscience-related distribution employed nearly 668,000 people, pharmaceutical manufacturing nearly 364,000, and agricultural feedstock and industrial biosciences approximately 71,300.[63]
- Pricing
- U.S. bioscience workers earned an average of $145,188 in 2025, which was $66,325, or 84%, above the overall private-sector average. Bioscience-related distribution had the highest average wages among the five U.S. subsectors in the cited state-level analysis, at $148,352 in 2025.[63][84]
- Trends, drivers & challenges
- U.S. bioscience employment rose 7.0% from 2021 to 2025, but growth slowed to 0.4% in 2025 after a 0.3% decline in 2024. The industry continues to benefit from research, manufacturing and distribution investment, while facing a cooling labor market, long development cycles, capital intensity and regulatory uncertainty.[63][57]
- Consumer behavior & competition
- Competition is increasingly centered on late-stage, clinically validated assets and specialized technologies rather than broad deal volume. In 2025, global life-sciences deal activity declined 12% year over year, while IQVIA reported that companies prioritized quality, strategic focus and de-risked assets.[57]
- M&A
- Biotechnology recorded 795 M&A transactions in 2025, down 11% from 2024. Financial investors accounted for 59% of biotechnology transactions, compared with 41% for industrial investors; across the broader life-sciences sector, M&A value rose sharply despite a 7% decline in M&A volume.[85][57]
- Regulation
- The U.S. Food and Drug Administration's Center for Drug Evaluation and Research approved 46 novel drugs in 2025. The agency defines novel drugs as products never previously approved or marketed in the United States, making this a key annual indicator of regulatory output.[86]
- Latest news
- On October 28, 2026, BIO and the Council of State Bioscience Associations reported that U.S. bioscience companies employed 2.31 million people across more than 156,000 establishments in 2025 and supported 9.67 million direct, indirect and induced jobs.[63]
02 Ranking
Top 10 Companies in the Bioscience Industry
The leading companies in the bioscience industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 11, 2026 · Next review December 11, 2026
Eli Lilly and Company stands out for innovative medicines and biologics because its operating margin was 40.4% in 2025, while Roche focuses on pharmaceuticals and diagnostics since its R&D was 19.8% of revenue in 2025.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in biopharmaceuticals
Eli Lilly and Company
US
Ranked #1 · 9.6 · Biopharmaceuticals
Why we picked it: It supports innovative medicines and biologics with an operating margin of 40.4% in 2025 and R&D at 20.5% of revenue.
#2 overall
Roche
CH
Ranked #2 · 9.0 · Biopharmaceuticals
Why we picked it: It combines pharmaceuticals and diagnostics, and it invests 19.8% of revenue in R&D.
#3 overall
Novartis
CH
Ranked #3 · 9.0 · Biopharmaceuticals
Why we picked it: It develops medicines across cardiovascular, immunology, neuroscience and oncology with a 32.4% operating margin in 2025.
Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly and Company Biopharmaceuticals · US | 9.6 | 9.6 | 9.9 | 9.9 | 9.9 | |
Company snapshot · Eli Lilly and Company · Data as of November 11, 2026 Lilly develops medicines addressing major health challenges, including diabetes, obesity and cancer.[87]
| |||||||
| 2 | Roche Biopharmaceuticals · CH | 9.0 | 9.9 | 7.7 | 8.8 | 9.9 | |
Company snapshot · Roche · Data as of November 11, 2026 Roche combines innovative medicines with in-vitro diagnostics and genomic technologies.[88]
| |||||||
| 3 | Novartis Biopharmaceuticals · CH | 9.0 | 9.7 | 8.6 | 8.4 | 9.5 | |
Company snapshot · Novartis · Data as of November 11, 2026 Novartis develops medicines in cardiovascular, immunology, neuroscience and oncology.[89]
| |||||||
| 4 | Novo Nordisk Biopharmaceuticals · DK | 8.9 | 9.6 | 8.5 | 8.0 | 9.9 | |
Company snapshot · Novo Nordisk · Data as of November 11, 2026 Novo Nordisk reached 45.6 million people living with obesity and diabetes in 2025.[90]
| |||||||
| 5 | AbbVie Biopharmaceuticals · US | 8.9 | 9.3 | 8.4 | 8.5 | 9.5 | |
Company snapshot · AbbVie · Data as of November 11, 2026 AbbVie reported $61.2 billion in 2025 net revenues from its biopharmaceutical portfolio.[91]
| |||||||
| 6 | Johnson & Johnson Pharmaceuticals and medical technologies · US | 8.7 | 9.5 | 7.5 | 8.3 | 9.5 | |
Company snapshot · Johnson & Johnson · Data as of November 11, 2026 Johnson & Johnson reported $94.2 billion in 2025 sales across medicines and MedTech.[92]
| |||||||
| 7 | Merck Biopharmaceuticals, vaccines and animal health · US | 8.6 | 9.7 | 8.1 | 7.0 | 9.5 | |
Company snapshot · Merck · Data as of November 11, 2026 Merck develops and delivers prescription medicines, vaccines, biologic therapies and animal-health products.[93]
| |||||||
| 8 | Pfizer Biopharmaceuticals and vaccines · US | 8.6 | 9.7 | 7.7 | 7.3 | 9.1 | |
Company snapshot · Pfizer · Data as of November 11, 2026 Pfizer supplies medicines and vaccines in approximately 200 countries and territories.[94]
| |||||||
| 9 | Gilead Sciences Antiviral, oncology and specialty medicines · US | 7.7 | 7.0 | 7.0 | 7.8 | 9.2 | |
Company snapshot · Gilead Sciences · Data as of November 11, 2026 Gilead develops and commercializes medicines for HIV, liver diseases, cancer and other serious conditions.[95]
| |||||||
| 10 | Danaher Life-science tools, diagnostics and bioprocessing · US | 7.4 | 7.0 | 7.6 | 7.5 | 8.0 | |
Company snapshot · Danaher · Data as of November 11, 2026 Danaher operates major life-science, diagnostics and bioprocessing businesses.[96]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 11, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 11). Top 10 companies in the bioscience industry. In Bioscience Industry Statistics. Gitnux. https://gitnux.org/bioscience-industry-statistics/#top-companies
Canadian research and development pharmaceutical sector total output (value of goods and services) (Canada)
Canadian research and development pharmaceutical sector total output (value of goods and services) grew from 27.9B Canadian dollars in 2018 to 34.2B Canadian dollars in 2022.
03 Trends & forecasts
Top 10 Bioscience Industry Trends & Forecasts 2027
What is changing in the bioscience industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Biotechnology growth remains double-digit
Medium confidenceThe global biotechnology market was valued at $1,376.1 billion in 2025 and is projected to reach $4,334.8 billion by 2034, implying a 14.3% CAGR from 2026 to 2034. North America held 43.34% of the market in 2025, keeping the region at the center of global demand and investment.[83]
Forecast 2027: The market should continue expanding rapidly in 2027, with growth led by biopharmaceuticals, advanced therapies, diagnostics and bioinformatics. North America is likely to remain the largest regional market, although Asia-linked development and licensing activity should increase.
02U.S. bioscience employment growth moderates
High confidenceU.S. bioscience employed 2.31 million people across more than 156,000 establishments in 2025, while employment increased 7.0% from 2021 to 2025. However, growth slowed to 0.4% in 2025 after a 0.3% decline in 2024.[63]
Forecast 2027: Employment growth is likely to remain positive but modest in 2027 as companies emphasize productivity, automation and late-stage programs. Hiring should be strongest in manufacturing, clinical development, data science and specialized laboratory roles.
03Bioscience venture funding partially recovers
High confidenceU.S. bioscience-related venture investment rose from $43.7 billion in 2023 to $51.0 billion in 2024 and $55.4 billion in 2025, but remained below the $87.7 billion recorded in 2021. BIO also reported that early-stage funding has become scarcer, with Series A-1 investment weakening in 2025.[63]
Forecast 2027: Funding should improve selectively in 2027 rather than return broadly to pandemic-era levels. Investors are likely to favor clinical validation, platform differentiation and clear partnering or exit paths, leaving preclinical companies under greater pressure to extend runway.
04R&D output stays resilient despite longer timelines
High confidenceIQVIA reported 79 novel active substances launched globally in 2025, including 30 global first-in-class launches. At the same time, overall development timelines lengthened, with inter-trial intervals increasing by three months.[57]
Forecast 2027: 2027 should bring continued high scientific output but limited improvement in end-to-end development speed. Sponsors will increasingly invest in trial-site efficiency, patient recruitment, protocol simplification and external development capabilities.
05AI moves into operational drug development
Medium confidenceIQVIA found early evidence of stronger clinical success rates for AI-enabled programs among emerging biopharma companies and reported that AI is increasingly used in discovery, clinical planning, trial operations, portfolio decisions and regulatory work.[57]
Forecast 2027: In 2027, AI adoption should broaden from target discovery into patient recruitment, trial monitoring, data review and regulatory document preparation. Commercial impact will remain uneven because validation, data quality, governance and integration with existing systems will constrain deployment.
06Clinical development becomes more selective
High confidenceIQVIA reported that most therapeutic areas experienced small declines in trial starts between 2024 and 2025, while oncology trial starts declined 4% overall. Oncology Phase II and Phase III starts nevertheless increased 3% and 4%, respectively, indicating greater concentration in later, more informative development stages.[57]
Forecast 2027: Trial portfolios should remain selective in 2027, with sponsors prioritizing programs that have stronger biological rationale, biomarker strategies and commercial differentiation. Early-stage programs without a clear path to proof of concept are likely to face greater partnering and financing difficulty.
07Novel oncology modalities gain share
High confidenceOne-third of oncology trials starting in 2025 involved novel modalities, including antibody-drug conjugates, radiopharmaceuticals, cell and gene therapies and multispecific antibodies. This shows that oncology competition is shifting toward modality and platform differentiation rather than conventional small-molecule volume alone.[57]
Forecast 2027: Novel oncology modalities should account for a larger share of new programs in 2027, particularly antibody-drug conjugates, radiopharmaceuticals and multispecific antibodies. Manufacturing complexity, safety management and treatment-center capacity will remain important constraints on commercialization.
08China-linked partnerships expand
High confidenceIQVIA reported that deals between China-headquartered and international companies reached an all-time high in 2025, even as trial starts from China-headquartered sponsors declined. The pattern indicates stronger cross-border licensing and partnering around selected assets rather than uniform expansion of domestic clinical activity.[57]
Forecast 2027: China-linked licensing and co-development should remain a major competitive force in 2027, especially in oncology and other high-value therapeutic areas. Geopolitical scrutiny, data controls and supply-chain concerns will make transaction structure and geographic rights more important.
09Dealmaking favors larger, de-risked assets
High confidenceIQVIA described 2025 as a year of fewer transactions but significantly higher deal values, with companies prioritizing quality, late-stage assets and strategic focus. IQVIA also reported that aggregate biopharma M&A value more than doubled to $133 billion in 2025.[57]
Forecast 2027: In 2027, M&A and licensing should remain concentrated around Phase II, Phase III and commercial assets with differentiated efficacy or defensible platforms. Smaller private companies will increasingly use partnerships, option deals and regional licensing to finance development instead of relying solely on IPOs.
10Regulatory flexibility supports advanced therapies
High confidenceIn 2026, FDA issued guidance allowing greater flexibility in chemistry, manufacturing and controls requirements for cellular and gene therapies and published a draft framework for using prior platform knowledge in genome-editing submissions. FDA also issued final guidance on potency assurance for cell and gene therapy products in November 2026.[86]
Forecast 2027: These measures should reduce duplicated work and improve regulatory predictability for advanced-therapy developers in 2027. The benefit will be greatest for sponsors with reusable manufacturing platforms, robust comparability data and strong post-approval monitoring plans.
04 Statistics
Technology & Innovation
Agentic-AI and automation are moving from discussion into operational scopes, with 74% using AI in 2025 and 27% to 54% adopting robotics and automation in 2024 by company size.
AI in the bioscience industry
- 66% of biopharma organizations considered agentic-AI implementation important or very important in 2025.[1]
- 67% of large biopharma companies and 23% of small biopharma companies had adopted AI or machine learning in 2024 in the United States and Europe.[2]
- 55% of AI-adopting biopharma companies used AI in process development in 2024, including cell-line development, bioprocessing, formulation design and digital twins.[2]
- 74% of pharma and biotech respondents were actively using AI in 2025, according to a global healthcare and life-sciences survey.[3]
- 80% of pharma and biotech respondents identified data analytics and data science as an AI focus area in 2025.[3]
Automation in the bioscience industry
Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)
- 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[5]
- 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[6]
- 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[5]
- 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[7]
- 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[6]
Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)
- 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[4]
- 63% of global biopharma respondents had adopted robotics and automation in 2023.[8]
- 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[8]
- 55% of biopharma AI adopters reported using AI in process development in 2024.[2]
- 70% of global biopharma respondents had adopted an R&D data platform in 2023.[8]
Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)
- 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[2]
- 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[9]
- 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[8]
- 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[2]
- 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[10]
Big Data in the pharmaceuticals and biotech sector (sector benchmark)
- 68% of pharmaceutical companies surveyed planned to use advanced analytics in 2024.[11]
- 33% of biopharma survey respondents reported using data lakes in day-to-day operations in 2021.[10]
- 49% of clinical-research survey respondents reported using AI and big-data analytics in drug development in 2024.[6]
- 55% of large pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[7]
- 48% of pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[7]
- 43% of small and midsize pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[7]
05 Statistics
Data & Analytics
Data readiness remains the gating factor for AI scaling: 96% of biopharma leaders said their data was not ready for artificial intelligence in 2025, and 81% cited accuracy and confidence as critical in 2026.
Business intelligence in the bioscience industry
- 14% of surveyed life-sciences companies were extremely confident in their data insights in 2024.[13]
- Four data sources and four consultants were used on average for a life-sciences data project in 2024.[13]
- 96% of surveyed biopharma leaders said their data was not ready for artificial intelligence in 2025.[14]
- 72% of surveyed life-sciences companies spent up to 100 days per year matching healthcare-professional data across sources in 2025.[14]
Data analytics in the bioscience industry
- 62% of surveyed life-sciences R&D experts identified AI and machine learning as planned top technology investments for the next two years in 2024.[15]
- 43% of small and mid-sized biopharma respondents planned to pursue big data and analytics in 2024.[7]
- 68% of life-sciences R&D experts surveyed globally were using artificial intelligence or machine learning in 2024.[15]
- 55% of large biopharma respondents using AI had applied it to process development in 2024.[4]
Data Quality in the pharmaceuticals and biotech sector (sector benchmark)
- Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[16]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[16]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[16]
- Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[16]
- Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[17]
Data Governance in the pharmaceuticals and biotech sector (sector benchmark)
- Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[18]
- Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[15]
- Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[17]
- Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[15]
- Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[15]
KPIs in the bioscience industry
- 97% of surveyed pharmaceutical companies tracked inquiry volume as a medical-information KPI in 2024.[19]
- 65% of surveyed pharmaceutical companies tracked the number of medical-information documents created or updated in 2024.[19]
- 55% of surveyed pharmaceutical companies tracked escalation rate as a medical-information KPI in 2024.[19]
- 61% of surveyed pharmaceutical companies distinguished between metrics and KPIs in 2024.[19]
06 Statistics
Strategy & Growth
Growth continues while deals concentrate on de-risked assets, with biotechnology venture funding at $20.6 billion in 2025 and deal volume down 11% in biotechnology M&A.
Growth in the bioscience industry
Differentiation in the bioscience industry
- Johnson & Johnson ranked No. 5 in Gartner’s 2024 global Supply Chain Top 25, remaining in the top five for the fifth consecutive year.[21]
- Pfizer ranked No. 20 in Gartner’s 2024 global Supply Chain Top 25, its fourth consecutive year in the ranking.[21]
- AstraZeneca rose six positions to No. 12 in Gartner’s 2024 global Supply Chain Top 25.[21]
- Three of the ten leading life-sciences supply chains ranked in Gartner’s 2024 global Supply Chain Top 25: Johnson & Johnson, AstraZeneca and Pfizer.[21]
Mergers and acquisitions in the bioscience industry
- 24.3% higher odds of entering shortage within two years were associated with drugs involved in a pharmaceutical merger or acquisition compared with similar drugs.[22]
- 182 pharmaceutical-sector mergers and acquisitions were recorded in 2023, down from 267 in 2016.[22]
- 5.9% was the average increase in therapeutic-area market concentration during the 12 months after a pharmaceutical merger or acquisition.[22]
Strategic partnerships in the bioscience industry
- 187 biopharma partnerships were announced in 2024, the highest annual number since 2020.[23]
- $31 billion was the combined potential value of the ten largest biopharma partnerships announced in 2024.[24]
- $11.3 billion was the total upfront value of biopharma partnerships announced in 2024.[23]
- $182.5 billion was the total potential value of 434 biopharma research-and-development partnerships in 2024.[25]
07 Statistics
People & Workforce
Employment grows more slowly, while talent and retention pressures intensify; U.S. bioscience employment rose 7.0% from 2021 to 2025, and 35% of life-sciences employees considered leaving their organization in 2026.
Hiring in the bioscience industry
- More than 2.9 million unique U.S. life-sciences job postings were analyzed for workforce trends covering the four years through late 2024.[26]
- 0.8% was the decline in U.S. life-sciences employment between August 2023 and August 2024.[27]
- 46% of large biopharma companies and 17% of small biopharma companies said they could attract and hire skilled AI talent in 2024.[2]
Employee retention in the bioscience industry
- 35% of life-sciences employees across 20 countries were considering leaving their current organization in 2026.[28]
- 33% of life-sciences employees considering a move in 2026 cited greater stability and security as a reason.[28]
- 41% of life-sciences employees considering a move in 2026 cited improved work-life balance as a reason.[28]
- 34% of life-sciences employees considering a move in 2026 cited greater flexibility as a reason.[28]
Remote Work in the pharmaceuticals and biotech sector (sector benchmark)
- Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[29]
- Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[30]
- Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[31]
- Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[31]
Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)
- Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[32]
- Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[33]
- Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[29]
- Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[34]
Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)
- Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[35]
- At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[36]
- Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[35]
- Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[35]
DEI in the bioscience industry
- 68% of life-sciences professionals said diversity was an important factor when considering a new job in 2024.[37]
- More than 80% of biotechnology companies rated DEI as an important area of strategic focus in 2024.[38]
- 17 percentage points was the decline from 2022 to 2024 in the share of life-sciences professionals rating diversity important when considering employment.[37]
Change Management in the pharmaceuticals and biotech sector (sector benchmark)
- Across pharmaceutical-company respondents, organizations spent almost 14 months planning and initiating clinical-trial innovations before later evaluation, adoption, and implementation stages in 2022.[39]
- Among pharmaceutical and biotechnology executives surveyed, 26% expected to conduct a significant acquisition within the following 12 months in 2023.[40]
- Among 125 pharmaceutical and biotechnology executives surveyed, 68% said their organizations were actively increasing investments in change management in 2023.[40]
- Among pharmaceutical and biotechnology executives surveyed, 67% said their companies were using mergers and acquisitions to access talent or innovation in 2023.[40]
- Across 612 pharmaceutical-company respondents, clinical-trial innovations took an average of 69 months from planning to portfolio-wide implementation, excluding decentralized-trial adoption during COVID-19.[39]
08 Statistics
Customer & Sales
Omnichannel execution depends on cross-team connectivity, with 95% citing low connectivity as a top barrier to omnichannel success in 2025.
Customer experience in the bioscience industry
- 61% of healthcare providers said excellent pharmaceutical customer experience improved their view of the company in a 2021 survey.[41]
- 95% of biopharma and medtech respondents cited low connectivity across teams as a top barrier to omnichannel success in 2025.[42]
- 97% of biopharma and medtech commercial leaders agreed that omnichannel engagement was critical in 2025.[42]
- -10% was the average Net Promoter Score for pharmaceutical companies among more than 700 U.S. healthcare providers surveyed in 2025.[43]
- 26% was the highest pharmaceutical-company Net Promoter Score and -57% was the lowest among U.S. healthcare providers surveyed in 2025.[43]
Customer retention in the bioscience industry
- 67% of healthcare providers said excellent pharmaceutical customer experience improved their belief that the company understood their challenges and those of their patients.[41]
- 65% of healthcare providers surveyed by Deloitte agreed that strong partnerships with life-sciences companies would be ideal.[10]
09 Statistics
Marketing & Brand
Marketing in the bioscience industry
Digital marketing in the bioscience industry
- 73% of pharmaceutical and healthcare advertising professionals ranked performance-driven paid media among their most critical investments in 2024.[48]
- 35% of pharmaceutical and healthcare advertising professionals identified first-party-data mastery as a critical investment in 2024.[48]
- $13.3 million per brand was average pharma online-banner, display, digital and alert spending in 2022, down from $19.2 million in 2021.[49]
- 54% of pharmaceutical and healthcare advertising professionals identified measurement and attribution capabilities as critical investments in 2024.[48]
Branding in the bioscience industry
- 55% of pharmaceutical and healthcare advertising professionals ranked brand advertising among the most critical media investments in 2024.[48]
- 42% of pharmaceutical and healthcare advertising professionals ranked brand advertising as a critical investment in 2023.[48]
- 60% of brand-side pharma marketing respondents in a 2025 survey worked for companies with more than $10 billion in annual revenue.[50]
Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)
- 44% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their perception of a medication in 2024.[53]
- 10% of healthcare and pharmaceutical marketers said they did not invest in creator or influencer marketing in 2026, globally.[54]
- 4.5% of high-engagement prescription-drug promotion posts across Facebook, Instagram, TikTok and YouTube came from pharmaceutical companies in the United States in 2025.[55]
- 29% of healthcare and pharmaceutical marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, globally.[54]
- 50% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their prescribing choices in 2024.[53]
10 Statistics
Operations & Execution
Digitalization shows measured operational lift, with 50% of biopharma supply-chain leaders reporting improved yields and 48% reporting improved warehouse efficiency in 2023.
Process optimization in the bioscience industry
- 50% of biopharma supply-chain leaders reported improved risk-sensing from digitalization in 2023.[10]
- 33% of biopharma supply-chain leaders said their organizations were attempting a complete digital transformation of the supply chain in 2023.[10]
- 50% of biopharma supply-chain leaders reported improved yields from digitalization in 2023.[10]
- 48% of biopharma supply-chain leaders reported improved warehouse efficiency from digitalization in 2023.[10]
Operational efficiency in the bioscience industry
- 33% of biopharma survey respondents said their organizations were likely to scale digital twins, machine vision or deep learning for process improvements within five years.[10]
- 10% to 25% was the estimated potential reduction in addressable biopharma cost baselines from three manufacturing and network levers analyzed by BCG.[56]
- 25% of revenue was approximately the cost of goods sold for leading biopharma companies, according to BCG’s analysis.[56]
- 47% of biopharma supply-chain leaders reported improved cost-effective sourcing from digitalization in 2023.[10]
Quality management in the bioscience industry
- 48% of biopharma supply-chain leaders reported improved warehouse efficiencies from digitalization in 2023, an operational quality-control indicator.[10]
- 50% of biopharma supply-chain leaders reported improved risk-sensing from digitalization, supporting quality and assurance activities, in 2023.[10]
- 50% of biopharma supply-chain leaders reported enhanced yields from digitalization in 2023, indicating improved process consistency.[10]
- 33% of biopharma supply-chain leaders said their organizations were likely to scale machine vision for predictive maintenance within five years.[10]
Supply chain in the bioscience industry
- 33% of biopharma supply-chain leaders said their organizations were attempting to completely transform supply chains using digital technologies in 2023.[10]
- 48% of biopharma supply-chain leaders reported improved warehouse efficiency after digitalization in 2023.[10]
- 50% of biopharma supply-chain leaders reported better risk-sensing after digitalization in 2023.[10]
- 47% of biopharma supply-chain leaders reported more cost-effective sourcing after digitalization in 2023.[10]
Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)
- 67% of global biotech and pharma companies outsourced pharmacovigilance operations in 2024, according to an IQVIA industry report.[57]
- 74% of surveyed pharmaceutical and biotech R&D leaders ranked patient recruitment among the top five drug-development activities likely to be outsourced in 2023.[7]
- 12% of total API volume used in the United States was produced domestically in 2024, with most supply coming from India and the European Union.[58]
- 41% of surveyed pharmaceutical and biotech R&D leaders increased their use of functional-service-provider outsourcing versus two years earlier in 2023.[7]
- 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[57]
11 Statistics
Finance & Pricing
Drug development costs keep rising, with the average cost to bring a new drug to launch at $2.2 billion in 2024, up from $1.3 billion in 2013.
Pricing strategy in the bioscience industry
- $2.2 billion was the average cost to bring a new drug from discovery to launch in 2024, up from $1.3 billion in 2013.[59]
- 69% was the increase in average drug-development cost between 2013 and 2024, intensifying biopharma pricing pressure.[59]
- 23% of 2021 revenue was projected to come from drugs still under patent in 2031 for the biopharma industry analyzed by BCG.[56]
- 1% lower biopharma revenue was associated with a 1.5% reduction in R&D activity in research cited by Morningstar Sustainalytics.[59]
Cost reduction in the bioscience industry
- 28.5% of revenue was the weighted-average cost of goods sold for the top 20 pharmaceutical multinationals in 2020.[60]
- 10% to 25% was BCG’s estimated potential reduction in addressable biopharma cost baselines from selected manufacturing and supply-network levers.[56]
- 5% to 16% was the cost-base reduction targeted by major biopharma cost-optimization programs announced in the year to January 2026.[56]
- 2% to 8% was the workforce reduction targeted by major biopharma cost-optimization programs announced in the year to January 2026.[56]
Profitability in the bioscience industry
- 20% of revenue was the weighted-average R&D cost for the top 20 pharmaceutical multinational enterprises in 2020.[60]
- 28.6% of revenue was the weighted-average operating-expense ratio for the top 20 pharmaceutical multinational enterprises in 2020.[60]
- 23% was the average EBIT margin of the top 20 pharmaceutical multinational enterprises worldwide in 2020.[60]
- 24.4% was the reported 2020 EBIT share of revenue for the top 20 pharmaceutical companies in the cited cost-structure analysis.[60]
12 Statistics
Product & Service
R&D pipelines expand while service operations track medical-information throughput, including 77% of surveyed pharmaceutical companies tracking response turnaround time as a medical-information KPI in 2024.
Product development in the bioscience industry
- 42% of U.S. pharmaceutical companies reported introducing a new or significantly improved product or process during 2020–22.[61]
- More than 1,800 biopharmaceutical products were in clinical development in the United States or Europe as of June 1, 2024.[62]
- 18.5% was the R&D intensity of U.S. pharmaceutical and medicine manufacturers in 2024.[61]
- 63,468 clinical studies were active in the United States or Puerto Rico during 2021–25, with industry sponsoring 29%.[63]
Product lifecycle in the bioscience industry
- 28% of 825 medicines launched in the United States between 1991 and 2020 generated a positive lifetime economic return after costs, taxes and R&D investment.[57]
- 91 medicines exceeded an inflation-adjusted blockbuster threshold in 2024, compared with 19 in 2000.[57]
- 63% of global branded medicine sales at list prices came from blockbuster medicines in 2024.[57]
- The minimum lifetime revenue associated with a positive return rose to $11.9 billion for medicines launched during 2016–20.[57]
After-sales in the bioscience industry
- 414 life-science professionals worldwide reported recent customer-service or technical-support interactions in BioInformatics’ 2024 study.[64]
- 71% of surveyed pharmaceutical companies used medical-information contact centers to track service metrics in 2024.[19]
- 45% of surveyed pharmaceutical companies tracked service level as a medical-information KPI in 2024.[19]
- 77% of surveyed pharmaceutical companies tracked response turnaround time as a medical-information KPI in 2024.[19]
Value proposition in the bioscience industry
- 42% of surveyed biopharma companies reported improved relationships with regulators because of sustainability efforts in 2024.[65]
- 63% of surveyed biopharma companies said sustainability was imperative to differentiation and business growth in 2024.[65]
- 15% of surveyed biopharma companies tracking sustainability ROI said their initiatives exceeded expectations in 2024.[65]
- 55% of surveyed biopharma companies tracking sustainability ROI said their programs performed as expected in 2024.[65]
13 Statistics
Sustainability & Ethics
Measurement and risk concerns dominate, with 76% of surveyed biopharma companies saying they could not accurately measure sustainability ROI in 2024 and Scope 3 emissions 5.4 times Scope 1 and 2 in 2023.
Sustainability in the bioscience industry
- 76% of surveyed biopharma companies said they could not accurately measure sustainability return on investment in 2024.[65]
- 64% of surveyed biopharma companies believed poor sustainability performance placed their business at critical risk in 2024.[65]
- 62% of surveyed biopharma companies ranked sustainability as a top business priority for the next five years in 2024.[65]
- 50% of surveyed biopharmaceutical companies had started carbon-reduction initiatives in 2024.[66]
ESG in the bioscience industry
- Around 25% of surveyed biopharmaceutical companies had begun calculating emissions in 2024.[66]
- 70% of 86 European biotechnology and pharmaceutical companies scored between 31 and 70 points on a 0–100 ESG scale for fiscal year 2023.[67]
- More than half of surveyed biopharmaceutical companies said sustainability played a significant role in securing capital financing in 2024.[66]
- Around two-thirds of surveyed biopharmaceutical companies had a dedicated ESG employee in 2024.[66]
Carbon footprint in the bioscience industry
- Scope 3 emissions were 5.4 times Scope 1 and 2 emissions combined for public biotechnology and pharmaceutical companies in 2023.[68]
- 397 million tonnes of CO2-equivalent emissions were produced by the biotechnology and pharmaceutical sectors in 2023 across Scopes 1, 2 and 3.[68]
- 36 companies representing 56% of biotechnology and pharmaceutical sector revenue had committed to the UN Race to Zero in 2024.[68]
- 31% of 149 biotechnology and pharmaceutical companies analyzed had medium-term Scope 1 and 2 targets aligned with a 1.5°C pathway in 2024.[68]
- Scope 3 emissions were 6.5 times Scope 1 and 2 emissions combined for private biotechnology and pharmaceutical companies in 2023.[68]
14 Statistics
Risk, Compliance & Legal
Risk management is tied to data controls and continuity planning, where 52% of surveyed middle-market life sciences companies reported experiencing a cybersecurity breach and 52% reported having a business continuity plan in place.
Compliance in the bioscience industry
- 53% of therapeutics companies reported having GMP standards already achieved in 2024, compared with 27% reporting ICH Q-guidelines compliance.[69]
- Nearly 125,000 regulatory-affairs professionals worked across the global healthcare-products sector in 2024, including pharmaceuticals, medical devices and biotechnology.[70]
- 53% of life-sciences survey respondents named changing and increasing regulation among their top external risks in 2024, globally.[71]
- 45% of life-sciences survey respondents identified data privacy as one of their top internal risks in 2024, globally.[71]
Risk Management in the pharmaceuticals and biotech sector (sector benchmark)
- 52% of middle-market life sciences companies reported having a business continuity plan in place.[72]
- 44% of global life science firms reported no standardized or consistently effective intellectual-property risk-management process in 2024.[71]
- 90% of clinical trials managed by surveyed CROs included at least one risk-based monitoring or risk-based quality-management component in 2025.[73]
- 81% of middle-market life sciences companies said risk management was a top priority, rising to 90% among the fastest-growing organizations.[72]
- 85% of global life science firms had a formal business continuity process covering the whole business in 2024.[71]
Cybersecurity in the pharmaceuticals and biotech sector (sector benchmark)
- 52% of surveyed middle-market life sciences companies reported experiencing a cybersecurity breach.[72]
- 40% of surveyed pharmaceutical businesses experienced outages affecting productivity, safety, compliance, revenue, or brand image.[74]
- 27% of healthcare, biotechnology, and pharmaceutical respondents had little or no confidence in identifying where their data was stored in 2025.[75]
- 98% of surveyed pharmaceutical firms experienced at least one cybersecurity intrusion in the 12 months covered by Fortinet’s 2021 survey.[74]
- 28% of surveyed pharmaceutical businesses lost business-critical data or intellectual property because of cybersecurity incidents.[74]
Data Privacy in the pharmaceuticals and biotech sector (sector benchmark)
- 66% of pharma, biotech, and medical-device respondents said patient privacy presented a challenge when complying with journal data-sharing policies in 2024.[76]
- 61% of surveyed pharmaceuticals and life sciences organizations identified GDPR as a top-two privacy and compliance focus in 2024.[77]
- 39% of surveyed pharmaceuticals and life sciences organizations said they tagged and classified around three-quarters of their unstructured data in 2024.[77]
- Stricter privacy regulation was associated with an approximately 39% reduction in R&D spending by global pharmaceutical and biotechnology firms four years after implementation.[78]
- 84% of surveyed pharmaceuticals and life sciences organizations said measuring and managing sensitive-content compliance required some to significant improvement in 2024.[77]
Crisis Management in the pharmaceuticals and biotech sector (sector benchmark)
- 40% of surveyed pharmaceutical firms maintained inventory buffers of one to three months to protect against supply-chain disruption.[79]
- 52% of surveyed global life science firms identified contract-manufacturing issues as a major supply-chain risk for the following two years.[71]
- 61% of surveyed global life science firms identified panic buying and stockpiling as a major supply-chain risk for the following two years.[71]
- 50% of surveyed global life science firms identified logistics and warehousing shortages as a major supply-chain risk for the following two years.[71]
- 48% of surveyed global life science firms identified natural disasters as a major supply-chain risk for the following two years.[71]
15 Statistics
Globalization & Expansion
North America logistics and distribution scale is high, with nearly 4,900 orders per day fulfilled by U.S. specialty distributors in 2024 and 97% of U.S. specialty-drug volume handled by AmerisourceBergen, McKesson and Cardinal Health.
Globalization in the bioscience industry
- 13% of global biotechnology greenfield foreign direct investment went to China between 2003 and 2024.[80]
- 74% of biotechnology greenfield foreign direct investment was concentrated in the leading destinations in 2024, down from 88% in 2015.[80]
- 28% of global biotechnology greenfield foreign direct investment went to European Union member states between 2003 and 2024.[80]
- 31% of global biotechnology greenfield foreign direct investment went to the United States between 2003 and 2024.[80]
Supplier management in the bioscience industry
- Nearly 4,900 orders per day were fulfilled by U.S. specialty distributors in 2024.[81]
- 32,800 provider locations were served by specialty distributors in 2024 in the United States.[81]
- 38.3% was the weighted-average share of specialty-distributor sales represented by independent physician-owned and operated clinics in 2024.[81]
- 97% of U.S. specialty-drug volume was handled by AmerisourceBergen, McKesson and Cardinal Health, including their subsidiaries.[10]
Distribution channels in the bioscience industry
- 97% of U.S. specialty-drug volume moved through three full-line distributors and their subsidiaries in 2024.[10]
- 10.4% was the increase in sales through the traditional U.S. pharmaceutical distribution sector in 2024.[82]
- 6.4% of U.S. pharmaceutical sales went through specialty pharmacies in 2024, up from 5.2% in 2023.[82]
- 11.7% of U.S. pharmaceutical sales went through independent drug stores in 2024, down from 13.1% in 2023.[82]
Key questions about the bioscience industry
How large is the bioscience market in the U.S.?
What is the global biotechnology market growth outlook?
Which companies lead the bioscience industry?
What technology shifts are showing up in drug development and lab work?
How is the U.S. bioscience industry structured?
Where does data readiness constrain operational change?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 11). Bioscience Industry Statistics. Gitnux. https://gitnux.org/bioscience-industry-statistics
Samuel Norberg. "Bioscience Industry Statistics." Gitnux, 11 Nov 2026, https://gitnux.org/bioscience-industry-statistics.
Samuel Norberg. 2026. "Bioscience Industry Statistics." Gitnux. https://gitnux.org/bioscience-industry-statistics.
Sources & references
96 sources cited across this report
statnews.com
test.benchling.com
nvidia.com
ispe.org
pmlive.com
ppd.com
- techresearchinfo.com
insights.indegene.com
deloitte.com
pharmamanufacturing.com
monitor-industrial-ecosystems.ec.europa.eu
knowledge.komodohealth.com
pharmalive.com
pistoiaalliance.org
veeva.com
capgemini.com
pmc.ncbi.nlm.nih.gov
ey.com
gartner.com
aspe.hhs.gov
williamblair.com
nature.com
dealforma.com
- bioutah.org
- mcphs.edu
connect.gigroup.com
naceweb.org
- jthelander.com
- innovatebio.org
- biobuzz.io
massbio.org
assets.kpmg.com
cultureamp.com
- amneal.com
biospace.com
dev.bio.org
acrpnet.org
crowe.com
- dt-consulting.com
web-assets.bcg.com
zs.com
advertising.biocompare.com
axiobench.com
marketingcharts.com
- scorrmarketing.com
s3.amazonaws.com
axtria.com
health-union.com
apnews.com
sermo.com
- brand-news.it
jamanetwork.com
iqvia.com
richmondfed.org
connect.sustainalytics.com
financing.desa.un.org
ncses.nsf.gov
- makingpharmaindustry.it
- scienceandmedicinegroup.com
vertassets.blob.core.windows.net
pharma.be
ethifinance.com
mygreenlab.org
qualio.com
raps.org
- lifesciencesny.org
middlemarketcenter.org
acrohealth.org
fortinet.com
cpl.thalesgroup.com
- openpharma.blog
kiteworks.com
etla.fi
- insights.economistenterprise.com
oecd.org
chaindrugreview.com
hda.org
fortunebusinessinsights.com
- nclifesci.org
- translinkcf.com
fda.gov
lilly.com
roche.com
prod1.novartis.com
annualreport.novonordisk.com
investors.abbvie.com
investor.jnj.com
merck.com
investors.pfizer.com
investors.gilead.com
investors.danaher.com
Social media in the bioscience industry